PSTV•benzinga•
Plus Therapeutics Continues Rally On Friday - Here's Why
Summary
Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung cancer treatment.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 7, 2025 by benzinga